Methods of treating skin disorders
Methods of treating skin disorders are provided.
1 . A method of treating a subject who has psoriasis, the method comprising administering a multiple course of treatment of a soluble CD2-binding LFA-3 polypeptide to the subject, wherein the multiple course comprises multiple cycles of treatment, and wherein each cycle comprises an administration period and a rest period.
2 . The method of claim 1 , wherein the soluble CD2-binding LFA-3 polypeptide is an LFA-3 fusion protein.
3 . The method of claim 1 , wherein the soluble CD2-binding LFA-3 polypeptide is an LFA-3/immunoglobulin (Ig) fusion protein.
4 . The method of claim 1 , wherein the soluble CD2-binding LFA-3 polypeptide comprises a soluble LFA-3 polypeptide fused to all or part of an Ig heavy chain hinge region and all or part of a heavy chain constant region.
5 . The method of claim 1 , wherein the soluble CD2-binding LFA-3 polypeptide comprises a fusion protein consisting of the amino terminal 92 amino acids of mature LFA-3, the C-terminal 10 amino acids of a human IgG1 hinge region, a CH2 region of a human IgG1 heavy chain, and at least part of a CH3 region of a human IgG1 heavy chain.
6 . The method of claim 1 , wherein the soluble CD2-binding LFA-3 polypeptide is AMEVIVE ( FIG. 1 ).
7 . The method of claim 1 , wherein the soluble CD2-binding LFA-3 polypeptide is encoded by an insert contained in plasmid pSAB152, deposited with American Type Culture Collection under the accession number ATCC 68720.
8 . The method of claim 1 , wherein the multiple course comprises at least four cycles of treatment.
9 . The method of claim 1 , wherein the multiple course comprises at least five cycles of treatment.
10 . The method of claim 1 , wherein the multiple course comprises at least six cycles of treatment.
11 . The method of claim 1 , wherein the multiple course comprises at least seven cycles of treatment.
12 . The method of claim 1 , wherein the multiple course comprises at least eight cycles of treatment.
13 . The method of claim 1 , wherein the rest period of each successive cycle of the multiple course is longer than the rest period of a previous cycle in the multiple course.
14 . The method of claim 1 , wherein the rest period of the last cycle of the multiple course is at least 2 years.
15 . The method of claim 1 , wherein the rest period of the last cycle of the multiple course is at least 3 years.
16 . The method of claim 1 , wherein the administration period of each cycle of the multiple course is at least 8 weeks.
17 . The method of claim 1 , wherein the administration period of each cycle of the multiple course is at least 10 weeks.
18 . The method of claim 1 , wherein the administration period of each cycle of the multiple course is at least 12 weeks.
19 . The method of claim 1 , wherein the polypeptide is administered intramuscularly.
20 . The method of claim 1 , wherein the polypeptide is administered intravenously.
21 . The method of claim 1 , wherein the polypeptide is administered at a unit dosage ranging from 2 to 30 mg.
22 . The method of claim 1 , wherein the method further comprises administering to the subject an additional therapeutic or prophylactic agent during the multiple course of treatment.
23 . A method of treating a subject in need of treatment for psoriasis, the method comprising administering a multiple course of treatment of AMEVIVE ( FIG. 1 ) to the subject, wherein the multiple course of treatment comprises at least three cycles of treatment, each cycle of treatment comprising an administration period of once-weekly administration of AMEVIVE ( FIG. 1 ) for 12 weeks, followed by a rest period of at least 12 weeks.
24 . The method of claim 23 , wherein the multiple course of treatment comprises at least four cycles of treatment.
25 . The method of claim 23 , wherein the multiple course of treatment comprises at least five cycles of treatment.
26 . The method of claim 23 , wherein the method comprises evaluating the subject for the effects of AMEVIVE ( FIG. 1 ) during one or both of the administration period and the rest period of each cycle in the multiple course.
27 . The method of claim 23 , wherein the method further comprises administering to the subject an additional therapeutic or prophylactic agent during the multiple course of treatment.
28 . A method of treating a subject having psoriasis, the method comprising (a) selecting a subject on the basis of having had at least two cycles of treatment with a soluble CD2-binding LFA-3 polypeptide and (b) administering a third cycle of treatment of a soluble CD2-binding LFA-3 polypeptide to the subject.
29 . The method of claim 28 , wherein the soluble CD2-binding LFA-3 polypeptide is AMEVIVE ( FIG. 1 ).
30 . A kit comprising a pharmaceutical composition comprising AMEVIVE and instructions to administer the pharmaceutical composition to a patient who has previously had two cycles of treatment with AMEVIVE ( FIG. 1 ).